These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17919347)

  • 61. Current controversies in the treatment of ductal carcinoma in situ of the breast.
    Franceschini G; Terribile D; Magno S; Fabbri C; D'Alba P; Chiesa F; Di Leone A; Scafetta I; Masetti R
    Ann Ital Chir; 2008; 79(3):151-5. PubMed ID: 18958961
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI; Malone KE; Saltzman BS; Daling JR
    Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Low-grade ductal carcinoma in situ (DCIS) arising in a fibroadenoma of the breast during 5 years follow-up: A case report.
    Shojaku H; Hori R; Yoshida T; Matsui K; Shimada K; Takayanagi N; Noguchi K
    Medicine (Baltimore); 2021 Mar; 100(10):e24023. PubMed ID: 33725814
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ductal carcinoma in-situ arising within benign phyllodes tumours.
    Lui SA; Oh HB; Wang S; Chan CW
    Ann R Coll Surg Engl; 2018 Apr; 100(4):e97-e102. PubMed ID: 29484937
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The management of ductal carcinoma in situ of the breast: a screened population-based analysis.
    Rakovitch E; Pignol JP; Chartier C; Hanna W; Kahn H; Wong J; Mai V; Paszat L
    Breast Cancer Res Treat; 2007 Mar; 101(3):335-47. PubMed ID: 16838110
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ductal carcinoma in situ: treatment or active surveillance?
    Kuerer HM
    Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast.
    Boughey JC; Gonzalez RJ; Bonner E; Kuerer HM
    Oncologist; 2007 Nov; 12(11):1276-87. PubMed ID: 18055847
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Ductal carcinoma in situ in 2019: Diagnosis, treatment, prognosis].
    Cutuli B
    Presse Med; 2019 Oct; 48(10):1112-1122. PubMed ID: 31653542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The management of ductal carcinoma in situ: current controversies and future directions.
    Masson S; Bahl A
    Clin Oncol (R Coll Radiol); 2013 May; 25(5):275-82. PubMed ID: 23453783
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapeutic strategy for ductal carcinoma in situ patients according to Van Nuys Prognostic Index.
    Andretta M; Scomersi S; Urbani M; Bortul M
    Ann Ital Chir; 2014; 85(3):254-9. PubMed ID: 25074533
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
    Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
    Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ.
    Williamson D; Dinniwell R; Fung S; Pintilie M; Done SJ; Fyles AW
    Radiother Oncol; 2010 Jun; 95(3):317-20. PubMed ID: 20400190
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
    Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
    Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is DCIS breast cancer, and how do I treat it?
    Bijker N; Donker M; Wesseling J; den Heeten GJ; Rutgers EJ
    Curr Treat Options Oncol; 2013 Mar; 14(1):75-87. PubMed ID: 23239193
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is DCIS Overrated?
    Feinberg J; Wetstone R; Greenstein D; Borgen P
    Cancer Treat Res; 2018; 173():53-72. PubMed ID: 29349758
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ.
    Wilkinson JB; Vicini FA; Shah C; Shaitelman S; Jawad MS; Ye H; Kestin LL; Goldstein NS; Martinez AA; Benitez P; Chen PY
    Ann Surg Oncol; 2012 Nov; 19(12):3785-91. PubMed ID: 22644510
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of ductal carcinoma in situ in the modern era.
    Khan A; Dumitru D; Catanuto G; Rocco N; Nava MB; Benson J
    Minerva Chir; 2018 Jun; 73(3):303-313. PubMed ID: 29589680
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epidemiology of ductal carcinoma in situ.
    Kerlikowske K
    J Natl Cancer Inst Monogr; 2010; 2010(41):139-41. PubMed ID: 20956818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.